<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458899</url>
  </required_header>
  <id_info>
    <org_study_id>D4130C00025</org_study_id>
    <nct_id>NCT01458899</nct_id>
  </id_info>
  <brief_title>Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214</brief_title>
  <acronym>TC-5214</acronym>
  <official_title>Phase I, Open-label, Randomized, Single-dose, Two Treatment (Fed Versus Fasted) Crossover Study to Assess the Effects of Food on the Pharmacokinetics of TC-5214 (S-Mecamylamine) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      (Food versus no food) crossover study to measure the effects of food on pharmacokinetics of
      TC-5214 (S-Mecamylamine) in healthy Subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I, Open-label, Randomized, Single-dose, Two treatment (Fed Versus Fasted) Crossover
      Study to Assess the Effects of Food on the Pharmacokinetics of TC-5214 (S-Mecamylamine) in
      Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TC-5214 area under the plasma concentration time curve will be measured.</measure>
    <time_frame>Pre dose, 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 7, 12, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TC-5214 maximum plasma concentration will be measured</measure>
    <time_frame>Pre dose, 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 7, 12, 24, 36, 48 and 72 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events</measure>
    <time_frame>During day - 1, day 1, 2, 3 and 4 of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in laboratory assessments</measure>
    <time_frame>During day - 1 and day 3 of visits 2 and 3 of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in vital signs</measure>
    <time_frame>During day - 1, day 1, 2, 3 and 4 of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A change from baseline in physical examination</measure>
    <time_frame>During day -1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacokinetics (PK) of TC-5214 in terms of area under the curve over the time (AUC) and maximum concentration (Cmax) and terminal half-life</measure>
    <time_frame>PK samles collected at pre dose, 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 7, 12, 24, 36, 48 and 72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of urine pharmacokinetics (PK) of TC-5214 in terms of the cumulative amount of drug excreted unchanged into urine from zero to time and renal clearance</measure>
    <time_frame>PK samples collected at pre dose, 0 - 12, 12 - 24, 24 to 48 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>A - first fed then fasted treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - first fasted then fed treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <description>Oral tablets, single 4mg dose</description>
    <arm_group_label>A - first fed then fasted treatment</arm_group_label>
    <arm_group_label>B - first fasted then fed treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, written, and dated informed consent prior to any study specific
             procedures.

          -  Healthy male and nonpregnant, nonlactating female 18 to 55 years, inclusive, with
             suitable veins for cannulation or repeated venipuncture.

          -  Have a body mass index (BMI) between 19 and 32 kg/m2 and weigh at least 50 kg

          -  Be willing to eat the high-calorie, high-fat breakfast or fast accordingly

          -  Be able to understand and comply with the requirements of the study as judged by the
             Investigator

        Exclusion Criteria:

          -  History of any clinically significant medical, neurologic, or psychiatric disease or
             disorder which, in the opinion of the Investigator and Sponsor, may either put the
             volunteer at risk because of participation in the study, or influence the results

          -  History of gastrointestinal surgery (except for appendectomy) or unintentional rapid
             weight loss

          -  History of seizure activity, including febrile seizures

          -  Past diagnosis of more than 1 episode of major depression

          -  History or presence of gastrointestinal, hepatic, or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans A Eriksson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Kvambergagatan 12, 15185, Sodertalje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc. Overland Park US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Smyth, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca 180 Concord Pike Wilmington, DE 19850-5437</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy male</keyword>
  <keyword>nonpregnant female</keyword>
  <keyword>volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>TC 5214</keyword>
  <keyword>The effect of food on the pharmacokinetics of TC-5214</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

